A Role for the alpha vbeta 3 Integrin in the Transmigration of Monocytes

Dheepika Weerasinghe,* Kevin P. McHugh,Dagger Frederick P. Ross,Dagger Eric J. Brown,§ Roland H. Gisler,* and Beat A. Imhof*parallel

* Basel Institute for Immunology, CH-4005 Basel, Switzerland; Dagger  Department of Pathology, and § Department of Internal Medicine, Washington University Medical Centre, St. Louis, Missouri 63110; and parallel  Department of Pathology, Centre Médical Universitaire, CH-1211 Geneva, Switzerland

    Abstract
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The beta 2 integrins and intercellular adhesion molecule-1 (ICAM-1) are important for monocyte migration through inflammatory endothelium. Here we demonstrate that the integrin alpha vbeta 3 is also a key player in this process. In an in vitro transendothelial migration assay, monocytes lacking beta 3 integrins revealed weak migratory ability, whereas monocytes expressing beta 3 integrins engaged in stronger migration. This migration could be partially blocked by antibodies against the integrin chains alpha L, beta 2, alpha v, or IAP, a protein functionally associated with alpha vbeta 3 integrin. Transfection of beta 3 integrin chain cDNA into monocytes lacking beta 3 integrins resulted in expression of the alpha vbeta 3 integrin and conferred on these cells an enhanced ability to transmigrate through cell monolayers expressing ICAM-1. These monocytes also engaged in alpha Lbeta 2-dependent locomotion on recombinant ICAM-1 which was enhanced by alpha vbeta 3 integrin occupancy. Antibodies against IAP were able to revert this alpha vbeta 3 integrin-dependent cell locomotion to control levels. Finally, adhesion assays revealed that occupancy of alpha vbeta 3 integrin could decrease monocyte binding to ICAM-1.

In conclusion, we show that alpha vbeta 3 integrin modulates alpha Lbeta 2 integrin-dependent monocyte adhesion to and migration on ICAM-1. This could represent a novel mechanism to promote monocyte motility on vascular ICAM-1 and initiate subsequent transendothelial migration.

Key words: monocytealpha vbeta 3 integrinalpha Lbeta 2 integrinmigrationICAM-1
    Introduction
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

MONOCYTES are among the first leukocytes to enter inflamed tissue where they play a vital role in the healing process. These cells, like other leukocytes, leave the circulation by crossing the vascular endothelium. The dynamic process of transendothelial migration (TEM)1 in vivo is a multistep mechanism. It includes initial tethering of leukocytes to the vessel wall, followed by rolling along the endothelium, tight adhesion to the endothelial surface, and ultimately movement of the leukocyte through the intercellular junctions into the underlying tissue (9, 20, 66). The selectin family of adhesion molecules and their ligands have been implicated in the initial tethering of leukocytes to the vessel wall through weak adhesions that permit leukocytes to roll in the direction of flow (40). Another class of adhesion molecules, the integrins, of which beta 1 and beta 2 are key players in TEM (1, 34, 65, 70), mediate arrest, tight adhesion, and spreading of leukocytes on the endothelium (2). Cellular activation precedes integrin-mediated adhesion and chemoattractants are potent activators in vivo (34, 68).

Monocytes express a selection of adhesion molecules including selectins, beta 1, beta 2, and alpha v integrins (28, 45). The beta 1 integrin alpha 4beta 1 present on monocytes promotes arrest and adhesion to vascular cell adhesion molecule-1 (VCAM-1) on the vascular endothelium (1). The beta 2 integrins alpha Lbeta 2 and alpha Mbeta 2 (CD11a/CD18 and CD11b/CD18, respectively) also present on monocytes (60), bind to the endothelial ligand ICAM-1 (CD54) (17, 65), and mediate tight adhesion to the endothelium (70). However, this presents a paradox: if beta 2 integrins mediate tight adhesion of a leukocyte to ICAM-1, how does the cell initiate the motility necessary for subsequent diapedesis? The cell must be able to modulate adhesions at the cell surface in order to move forward. It was recently shown that alpha Lbeta 2 on lymphocytes can downregulate alpha 4beta 1 integrin activity and enhance cell motility on fibronectin (52). We have previously demonstrated that the alpha vbeta 3 integrin can regulate lymphocyte motility on VCAM-1 by modulating the function of alpha 4beta 1 (32).

The alpha vbeta 3 integrin can bind to multiple ligands in an Arg-Gly-Asp-dependent manner (22, 23). The integrin per se mediates cell locomotion and is involved in cell migration on components of the extracellular matrix (ECM) (11, 41). It can also modulate the activity of other integrins, such as phagocytosis mediated by alpha 5beta 1 (3) and adhesion through alpha Mbeta 2 (33, 71). The alpha vbeta 3 integrin has been shown to be physically and functionally associated with integrin-associated protein (IAP, CD47) (7), a 50-kD membrane protein found on a variety of different cell types (55), as antibodies against IAP can block some alpha vbeta 3 integrin-mediated functions (7, 44). IAP on its own is a receptor for the carboxy-terminal domain of thrombospondin-1 (25), and anti-IAP antibodies can block TEM of leukocytes at a step subsequent to tight adhesion (12). It was recently shown that certain forms of platelet endothelial cell adhesion molecule (PECAM-1)/CD31 are heterotypic ligands for alpha vbeta 3 integrin (8, 51). Interestingly, several groups have shown that antibodies against PECAM-1 are also able to block TEM (49, 72). Therefore, there is some evidence to suggest that the alpha vbeta 3 integrin might be involved in TEM.

We looked specifically at the role of alpha vbeta 3 integrin in monocyte migration. A beta 3 integrin-deficient monocytic cell line displayed poor migratory ability compared with a beta 3 integrin-positive monocytic cell line in TEM assays. Antibodies against alpha v or IAP inhibited transmigration of beta 3-positive monocytes. Moreover, transfection of the beta 3 chain into beta 3-deficient cells with subsequent expression of beta 3 integrins conferred on these cells an enhanced ability to transmigrate. In the process of elucidating the mechanism of this enhanced transmigration, we found that beta 3 integrin-positive monocytic cells preferentially transmigrated through ICAM-1-expressing cell monolayers. Subsequent studies of monocyte locomotion on recombinant ICAM-1 and adhesion assays revealed a cross talk mechanism between alpha vbeta 3 integrin and alpha Lbeta 2 integrin on monocytes which affects monocyte binding to and migration on ICAM-1.

Our results point to a role for the alpha vbeta 3 integrin in beta 2 integrin-dependent migration of monocytes on ICAM-1, which could be a mechanism that enables monocytes to overcome tight adhesion to endothelial ICAM-1 under inflammatory conditions and engage in subsequent TEM.

    Materials and Methods
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Lines

J774.2 and WEHI-3 murine monocytic cell lines were obtained from American Type Culture Collection (Rockville, MD). The mouse endothelioma cell line e.end2 was from W. Risau (Max-Planck, Bad Neuheim, Germany). Untransfected L cells and L cells transfected with full-length CD31 were obtained from S. Albelda (The Wistar Institute, Philadelphia, PA) and have previously been described (14). The L cells transfected with ICAM-1 were obtained from C. Figdor (University Hospital, Nijmengen, The Netherlands). The THP-1 human monocytic cell line was obtained from the lab of A. Lanzavecchia (The Basel Institute for Immunology, Basel, Switzerland).

Medium and Reagents

J774.2, e.end2, untransfected L cells, and L cells transfected with CD31 were grown in DME media (GIBCO BRL, Paisley, Scotland) supplemented with 10% FCS (GIBCO BRL, Auckland, New Zealand), nonessential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin (all from GIBCO BRL, Auckland) and 5 × 10-5 M 2-mercaptoethanol (Fluka, Buchs, Switzerland). WEHI-3 cells were grown in Iscove's modified Dulbecco's (IMDM) media (GIBCO BRL, Paisley) supplemented as above. Murine beta 3-transfected WEHI-3 cells were cultured in IMDM with 0.5 g/liter geneticin, (G418 sulfate from Calbiochem-Novabiochem Corp., La Jolla, CA). L cells transfected with ICAM-1 were cultured in IMDM with 1 g/liter of G418. The human monocytic cell line THP-1 was cultured in RPMI (GIBCO BRL, Paisley) with 10% FCS. Human unbilical vein endothelial cells (HUVEC) cells were obtained from U. Vischer (Centre Médical Universitaire, Geneva, Switzerland) at first or second passage.

The mouse soluble recombinant adhesion molecules ICAM-1, PECAM-1, and VCAM-1 have been previously described (51). Soluble recombinant human ICAM-1 was obtained from J.E. Meritt (Roche Products Ltd., Herts, UK). The mouse and human chemokine MCP-1 used in the transmigration assays were from R&D Systems, Inc. (Abingdon, UK). Mouse and human TNF-alpha and mouse laminin were all from GIBCO BRL (Paisley). Human plasma fibronectin and human plasma vitronectin were from Collaborative Research (Bedford, MA). BSA was from Sigma Chemical Co. (Buchs, Switzerland).

Other Reagents and Antibodies

For FACS® analysis the following antibodies were used: anti-beta 3, anti-alpha M, anti alpha 4, anti-CD31 (all from PharMingen, San Diego, CA), anti-MHC class II, anti-alpha v, anti-IAP, anti-alpha 6 (EA-1) (57) and anti-alpha L (see below). For TEM and migration assays on ICAM-1, only affinity-purified preservative-free antibodies were used. The anti-mouse antibodies were anti-alpha v integrin (RMV-7 from H. Yagita [Juntendo University, Tokyo, Japan]), anti-alpha L (FD441.8) (61), anti-alpha 4 (PS/2) (48), anti-IAP (MIAP 301) (43), anti MHC class II (M5/114) ATCC TIB 120, and anti-alpha 6 (GoH3) (53). The anti-human antibodies directed against the integrins beta 1 (JB1a), beta 2 (P489-A11), alpha vbeta 3 (LM609), alpha vbeta 5 (P1F6), and alpha v (CLB-706), and anti-MHC class I were all from Chemicon (Temecula, CA). Anti-human IAP (B6H12) has previously been described (7, 26). The anti-alpha L subunit function blocking antibody (mAb 38) was from the lab of N. Hogg (Imperial Cancer Research Fund, London, UK) (52).. For cross-linking experiments, the following secondary affinity-purified preservative-free polyclonal antibodies were used: Fc fragment-specific goat anti-rat IgG and Fc fragment-specific goat anti-mouse IgG (Chemicon). Rabbit antibodies against human fibronectin (Sigma Chemical Co., St. Louis, MO) or against human fibrinogen (Dako A/S, Copenhagen, Denmark), both cross-reactive with the mouse proteins, were used in the immunofluorescent studies. The secondary reagent was a FITC-labeled goat anti-rabbit antibody (Southern Biotechnologies, Birmingham, AL).

Isolation of Human Peripheral Blood Monocytes

Human blood from healthy donors was collected with heparin (Liquemin; Roche). Peripheral blood mononuclear cells were separated from whole blood by density gradient centrifugation using Ficoll-hypaque (Pharmacia Biotech., Inc., Dübendorf, Switzerland). Monocytes were then separated from the lymphocytes using a Percoll gradient (Pharmacia Biotech., Inc.). The isolated monocytes were used within 48 h for TEM assays or FACS® analysis, and cultured in RPMI medium with 10% FCS (Boehringer Mannheim, Mannheim, Germany).

Stable Transfection of the beta 3 Integrin Chain into WEHI-3 Cells

A 2.6-kb cDNA fragment containing the entire mouse beta 3 integrin coding region was excised from the pBluescript II KS- vector with BamHI and XhoI and then inserted into the pcDNA3 vector (Invitrogen, Leek, The Netherlands). WEHI-3 cells were transfected using the lipofectamine method. Briefly, 12 µg of DNA in a 50-µl volume was mixed with 30 µl of lipofectamine (GIBCO BRL, Basel, Switzerland) in a total volume of 100 µl with distilled water. After a 15-min incubation at room temperature, this was added dropwise to 5 × 106 WEHI-3 cells in 3 ml Opti-MEM (GIBCO BRL, Paisley). After 24 h at 37°C without serum, 3 ml of medium containing 20% FCS was added and cells were left for another 24 h at 37°C. Cells were then harvested and cultured in medium with 500 mg/ml geneticin and seeded at limiting dilution into 96-well plates. Colonies were picked 14 d later. Cell clones were expanded individually and clones expressing the beta 3 integrin chain were selected by FACS® analysis. These were then expanded further.

Flow Cytometry

Suspension and trypsinized adherent cells were collected and resuspended in Dulbecco's PBS with 1% BSA. Cells (105 per sample) were washed twice in this medium and then resuspended in DPBS/BSA with saturating amounts of mAbs. After a 30-min incubation at 4°C, cells were washed twice in DPBS/BSA and then resuspended in staining solution containing FITC-labeled goat anti-rat IgG (Jackson ImmunoResearch, Milan, Italy and Analytica, La Roche, Switzerland) for rat monoclonals, FITC-labeled goat anti-hamster IgG for hamster monoclonals, or FITC-labeled goat anti-rabbit IgG for antibodies raised in rabbit (Southern Biotechnologies, Birmingham, Alabama). After another 30-min incubation at 4°C, cells were washed twice, resuspended in the staining solution containing 0.1% propidium iodide, and then analyzed by flow cytometry (FACScan®; Becton Dickinson Co., Mountain View, CA). Control cell suspensions were incubated with secondary antibody alone.

Transendothelial Migration Assay

Transwell culture inserts of 24-well tissue culture plates (6.5-mm-diam polycarbonate membranes with 5 µm diameter pores [Costar Corp., Cambridge, MA]) were coated with 50 mg/ml laminin in Earle's balanced salt solution for 30 min. Excess laminin was removed from the inserts and e.end2 cells at 106/ml were seeded on the inserts in 100 µl of medium. Cells were allowed to grow to confluence on filters for 48 h. Cell confluence was checked by staining some filters with May-Grunwald-Wright- Giemsa solution (Fluka) followed by microscopic control. The cultures were then washed once in DME with 5% FCS and then preincubated in medium with or without 20 ng/ml of TNF-alpha for 5 h at 37°C, after which the cultures were washed twice with medium.

Cells of the J774.2 or WEHI-3 line were washed once in medium and then adjusted to 106 cells/ml. 100 µl of cell suspension were added per insert. Thereafter, 300 µl of medium were placed into the lower chambers of the Transwells with 125 ng/ml of monocyte chemoattractant protein-1 (MCP-1). The inserts were carefully placed into the lower chambers to avoid air bubbles forming at the interface between the underside of the insert and the medium. Migration was allowed to proceed for 4 h at 37°C. The assay was stopped by removing the medium from the upper well and rinsing the upper surface of the insert twice with 0.2% EDTA in PBS. The number of cells which had migrated into the lower chamber was determined by light microscopy at a magnification of 10. Alternatively for the human cell experiments, HUVECs were cultured for 48 h on filters precoated with 50 µg/ml fibronectin. The rest of the assay was as described before. However, freshly isolated human monocytes were allowed to transmigrate for 2 h.

For antibody-blocking studies, 300 µl of monocytic cells at 106 cells/ml were spun down and re-suspended in 100 µl of medium in an Eppendorf tube (Hamburg, Germany). The antibodies were added to a final concentration of 50 µg/ml. The tubes were then incubated on a shaker for 40 min at 4°C. Before the assay, cells were spun down, washed once in medium, and then resuspended in 300 µl of fresh medium. This was then added to three wells per condition. For each experiment, the number of cells which had transmigrated was expressed as the mean value of cells counted in three wells.

Transmigration through L Cells

Basically, the same method as for endothelial cells was used. Untransfected L cells, L cells expressing PECAM-1, or L cells expressing ICAM-1 were seeded at a concentration of 105 cells per well on laminin-precoated inserts and then allowed to grow to confluence for 48 h. Cultures were washed once in medium and monocytic cells were added in a 100-µl volume to the upper well. Chemokines were used at the same concentration as in the TEM assay. Cell confluence was checked as before. For this experiment, the mean value of transmigrated cells counted in three wells was expressed as a percentage of the total number of cells added per well.

Cell Migration Assay

Single wells of a 96-well plate (Serocluster; Costar Corp.) were coated with 2.4 µM of recombinant soluble adhesion molecules. This concentration has been shown to be the saturating concentration for a single well of a 96-well plate (32). A typical saturating coating consisted of either 100% mouse or human ICAM-1. In the case of mixes, the saturating coating consisted of 99% ICAM-1 and 1% CD31, obtained by mixing 2.376 µM of ICAM-1 and 0.024 µM of CD31. The total protein concentration remained at 2.4 µM. For the control experiments ~1% vitronectin or ~1% laminin was used. Wells were coated for 1 h with protein and then blocked for 1 h with 20% BSA, all at room temperature, after which wells were washed three times with serum-free medium. 105 cells in the exponential growth phase were washed once with 500 µl of serum-free medium, resuspended in 100 µl, added to a coated well, and then allowed to adhere at 37°C for 5 min. Nonadherent cells were washed away by gently adding 100 µl of medium to the well and exchanging this volume twice. The plate was then placed under an Axiovert 100 television microscope (Carl Zeiss AG, Jena, Germany) equipped with an incubator chamber. The temperature of the air and the microscope plate was maintained at 37°C by a TRZ 3700 unit and the CO2 level (10 or 5%) was controlled by a CTI controller 3700 (all from Carl Zeiss AG). Continuous recording of cell migration was performed using a 20× objective with video time-lapse equipment.

During incubation, antibodies were added manually in a volume of 10 µl using a Gilson pipette and a curved multiprecision tip (Sorenson Bioscience, Inc., Salt Lake City, Utah). Before the addition of antibody, cells were allowed to migrate on the substrate for 40 min in order to record locomotion in the absence of antibody. After antibody had been added, cell locomotion was recorded for another 40 min. To block molecules on the cell surface, anti-alpha L or anti-IAP antibodies were added at a final concentration of 50 µg/ml. To cross-link molecules, anti-alpha v, anti-beta 2, anti-alpha 6 or anti-major histocompatibility complex (MHC) antibodies were used at a final concentration of 10 µg/ml, together with 10 µg/ml of secondary anti-Fc-specific antibody.

Data Analysis

After completion of the assay, the video was played 60 times faster on a Sony color video television. The displacement of individual cells was traced on transparent write-on films. A minimum of 10 tracks were followed for 30 min in each experiment. Migration distance was measured in centimeters for each track using a curvimeter. Results are expressed in µm/h by using the conversion factor 8 cm = 100 µm.

Immunofluorescent Studies

L cells expressing ICAM-1 were trypsinized and cultured on eight chamber glass slides (Nunc, Inc., Naperville, IL) for 24 h. Cells were fixed in ice-cold acetone for 7 min and then allowed to air dry. Wells were blocked with 10% FCS in PBS for 30 min after which primary antibody was added at a 1:50 dilution in PBS/BSA. This was left at room temperature for 30 min, after which the secondary FITC-labeled antibody was added and left for another 30 min. Each step was followed by a washing step in PBS and distilled water.

Cell Bead Attachment Assay

Ligand-coated beads were prepared as described previously (52). Briefly, 200 µl (108) of 3.2-µm polystyrene beads (Sigma Chemical Co.) were washed twice in distilled water followed by two further washes and resuspension in 0.1 M bicarbonate buffer, pH 9. ICAM-1 or fibronectin (control) was added to the beads at a final concentration of 10 µg/ml. To prepare BSA-coated control beads, they were incubated with 2% BSA. The beads were rotated for 1 h, washed once in PBS and blocked with 2% BSA for 2 h, all at room temperature. Finally, the beads were washed twice in 20 mM Hepes, 140 mM NaCl, and 2 mg/ml glucose, pH 7.4 (assay buffer).

Multiwell Lab-Tek chamber slides (Nunc, Inc.) were coated overnight at 4°C with the following molecules: recombinant ICAM-1; vitronectin; anti-alpha vbeta 3, anti-alpha vbeta 5, anti-alpha 6, anti-beta 2, and anti-MHC class I antibodies; all at 50 µg/ml or BSA. The next day, the wells were washed twice with PBS and nonspecific binding sites were blocked with 2% BSA at room temperature for 2 h. THP-1 monocytic cells (150 µl of 2 × 106/ml) in assay buffer were added to the wells and allowed to settle on ice for 15 min. Freshly prepared ligand-coated beads were then added to the wells at a 100:1 bead/cell ratio in 50 µl of assay buffer. After 30 min at 37°C, unbound beads and cells were removed by washing the wells four times in prewarmed assay buffer. Bound cells were fixed with 1% formaldehyde in PBS for 20 min and the cells were then stained with haematoxylin for 10 min. 100 cells were counted under the microscope (40× oil immersion objective; Carl Zeiss AG, Jena, Germany) and the number of beads which had bound to these cells was determined (attachment index). For antibody-blocking studies, anti-alpha L (mAb38), anti-beta 1, or anti-alpha 6 was added to the cells at a final concentration of 50 µg/ml and left for 15 min at 4°C before the addition of beads.

    Results
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The alpha vbeta 3 Integrin Is Involved in Monocyte Transendothelial Migraton

To study molecules involved in TEM we set up an in vitro assay. A murine endothelial cell line was grown to confluence on laminin-precoated polycarbonate filters with defined 5-µm-diam pores. Several murine monocytic cell lines were screened for their ability to transmigrate. In vivo, monocytes preferentially home to acute inflammatory tissue. Inflammation is accompanied by increased expression of both ICAM-1 and VCAM-1 on the endothelium, which are essential molecules for leukocyte TEM (47). We therefore treated the endothelial monolayer with the inflammatory cytokine TNF-alpha , which led to increased expression levels of ICAM-1 and VCAM-1 as determined by FACS® analysis (data not shown). As a soluble gradient of endogenous chemokine promotes the TEM of monocytes in vitro (54), we included the chemokine MCP-1 in our assay (69). An optimal concentration of 125 ng/ml was chosen because MCP-1 has been shown to be maximally chemotactic at around this concentration (56). As expected, transmigration of monocytes was more efficient through the TNF-alpha -activated endothelial monolayer. The J774.2 monocytic cell line was able to selectively migrate through the endothelial monolayer, but not through plain filters or filters coated with ECM molecules alone (Fig. 1 and data not shown). In comparison, the WEHI-3 monocytic cell line transmigrated threefold less efficiently through the endothelial monolayer. We performed FACS® analysis on the J774.2 and WEHI-3 cells to quantitate the expression levels of different adhesion molecules known to play a role in leukocyte migration. Although both J774.2 and WEHI-3 cells expressed alpha L, alpha M, alpha 4, alpha 6 and alpha v integrin chains, and IAP, beta 3 integrin chain expression was markedly low on WEHI-3 cells (Fig. 2). There was no differential expression of PECAM-1 on the two murine cell lines (data not shown).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   In vitro migration of monocytic cells across an endothelial cell layer. Murine monocytic J774.2 and WEHI-3 cells were used in the TEM assay as described in Materials and Methods. J774.2 cells do not transmigrate through either plain filters or ECM-coated filters (data not shown). Transmigration was allowed to proceed across a preestablished layer of unactivated (dotted bars) or TNF-alpha -activated (solid bars) e.end2 endothelioma cells for 4 h at 37°C. Cells that had passed through the endothelial cell layer into the lower chamber were counted. J774.2 cells transmigrated more efficiently than WEHI-3 cells through nonactivated or activated endothelium. The results are expressed as the arithmetic mean of the number of cells ± SE from three wells per condition. A representative experiment out of three is shown.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.    Flow cytometry to determine expression levels of MHC class II, IAP, and the integrin chains alpha 6, beta 3, alpha v, alpha L, alpha M, and alpha 4 on the J774.2 and WEHI-3 murine monocytic cells. J774.2 cells expressed all the molecules tested, whereas beta 3 integrin chain expression was markedly low on WEHI-3 cells.

beta 3 integrins have not previously been described to play a role in monocyte TEM. However, previous experiments have shown that IAP plays a role in the TEM of some leukocyte subsets, whereas others have shown that IAP is necessary for some alpha vbeta 3-mediated functions (7). The adhesion molecule PECAM-1, found on circulating leukocytes and endothelial cells, is another molecule involved in TEM (49, 72). We previously demonstrated that some forms of PECAM-1 can interact with the alpha vbeta 3 integrin.

We investigated the effect of antibodies against the alpha v integrin chain in the in vitro assay. These antibodies were able to block TEM of J774.2 cells by 50% through TNF-alpha -activated endothelium as shown in Fig. 3 a. Antibodies against IAP, alpha L, and alpha 4 integrins but not against alpha 6 or MHC class II also blocked TEM under inflammatory conditions. Although these experiments reinstated the importance of IAP, alpha L, and alpha 4 for monocyte TEM, they also indicated that alpha v integrins were involved in the process. In a subsequent TEM assay using primary HUVEC cell cultures as the endothelial monolayer, we tested the ability of human peripheral blood monocytes to transmigrate under normal and inflammatory conditions. Antibodies against beta 2 and alpha v integrins were able to inhibit TEM across nonactivated endothelium by 50%, whereas anti-beta 1 had no effect (Fig. 3 b). This was consistent with the fact that nonactivated endothelium does not express the alpha 4beta 1 ligand VCAM-1. As a result of TNF-alpha treatment, HUVECs express VCAM-1, and ICAM-1 levels are increased (data not shown). This resulted in a twofold enhancement of TEM which could be inhibited by anti-beta 1, anti-beta 2, and anti-alpha v antibodies (Fig. 3 b). Control anti-MHC class I antibodies had no effect on TEM under either condition. Freshly isolated human monocytes express the alpha vbeta 3 integrin albeit at lower levels than beta 2 integrins (Fig. 3 c).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of murine and human monocyte TEM by antibodies against the alpha v integrin chain. Details of the TEM assay are described in Materials and Methods. (a) Effect of antibodies on TEM of murine J774.2 monocytic cells across a TNF-alpha -activated e.end2 endothelial monolayer. TEM in the absence of any antibody (cont) or in the presence of anti-MHC, anti-alpha 6, anti-alpha v, anti-IAP, anti-alpha L or anti-alpha 4. (b) Effect of different antibodies on TEM of freshly isolated human peripheral blood monocytes across a layer of nonactivated (dotted bars) or TNF-alpha -activated (solid bars) HUVEC cells. TEM was allowed to proceed at 37°C for 2 h. Antibodies against beta 2 or alpha v blocked TEM of cells under nonactivated conditions, whereas under activated conditions TEM increased and antibodies against beta 1, beta 2, or alpha v were able to block this. Results are the arithmetic means (± SE) of the number of cells from three wells per condition. A representative experiment out of three is shown. (c) FACS® analysis of freshly isolated human peripheral blood monocytes for expression of alpha vbeta 3 and beta 2 integrins. Human monocytes expressed alpha vbeta 3 albeit at lower levels than beta 2 integrins.

Enhanced TEM of WEHI-3 Cells Transfected with Full-length beta 3 cDNA

To clarify the importance of the alpha vbeta 3 integrin in TEM, beta 3-deficient WEHI-3 cells were transfected with full-length mouse beta 3 integrin cDNA. WEHI-3 clone 1D10 expressed beta 3 integrin chains and also showed increased expression levels of alpha v as compared with clone 3E9 which did not express beta 3 integrin chains (Fig. 4). A further WEHI-3 clone (1C10) expressing similar levels of the beta 3 integrin chain to clone 1D10 (data not shown), was also selected for subsequent TEM assays. The WEHI-3 beta 3+ clones 1D10 and 1C10 exhibited an enhanced ability to transmigrate under inflammatory conditions as compared with the beta 3- clone 3E9, and also surpassed J774.2 cells (Fig. 5 a). Furthermore, antibody-blocking studies on clone 1D10 and clone 3E9 cells showed that anti-alpha L and anti-alpha v integrin antibodies could inhibit TEM of clone 1D10 cells (Fig. 5 b). An antibody against alpha 6 integrin or MHC class II, had no effect on TEM.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   FACS® analysis of the expression levels of the alpha v and beta 3 integrin chains on WEHI-3 cells that had been transfected with full-length mouse beta 3 cDNA. (a) Clone 1D10 expressed the beta 3 integrin chain. (b) Clone 3E9 did not express the beta 3 integrin chain.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Migration of J774.2 or beta 3 chain transfected WEHI-3 monocytic cells across TNF-alpha -activated e.end2 endothelial monolayers. (a) Comparison of TEM of J774.2 and WEHI-3 clones. Clones 1D10 and 1C10 express beta 3 integrins. Clone 3E9 is a beta 3 nonexpressing clone. (b) Effect of antibodies against MHC class II, alpha v, alpha 6, or alpha L integrins on TEM of WEHI-3 beta 3+ clone 1D10 cells (solid bars) and WEHI-3 beta 3- clone 3E9 cells (hatched bars). TEM of clone 1D10 was inhibited by anti-alpha v or anti-alpha L integrin antibodies. (c) Comparison of the transmigratory capacity of the WEHI-3 parental cell line with clone 1D10 through laminin-coated filters or activated endothelium. Both the WEHI-3 parental cell line and clone 1D10 transmigrated at comparable levels through laminin-coated filters (hatched bars). However, only clone 1D10 cells were able to transmigrate through activated endothelium (solid bars). Details of the assays are described in Materials and Methods. Results are the arithmetic mean (± SE) of cells from three wells per condition. A representative experiment out of three is shown.

To compare the transmigratory capacity of the WEHI-3 parental cell line with clone 1D10, we compared their ability to transmigrate through an inflammatory endothelium versus plain laminin-coated filters. WEHI-3 and clone 1D10 cells transmigrated at comparable levels through laminin-coated filters. However, only clone 1D10 cells transmigrated significantly through inflammatory endothelium (Fig. 5 c). These experiments demonstrated the importance of the alpha vbeta 3 integrin in monocyte TEM.

Transmigration Is Increased through L Cells Expressing ICAM-1

Expression of the alpha vbeta 3 integrin is known to be required for cell migration on ECM substrates (11, 22, 58, 59). To examine how the alpha vbeta 3 integrin increases cell migration in our studies, we used a modified transmigration assay. Fibroblast type L cells, which express the alpha vbeta 3 ligand fibronectin (data not shown) were used in lieu of the endothelial monolayers and grown to confluence on nucleopore filters. Neither J774.2 nor WEHI-3 beta 3+ clone 1D10 cells were able to transmigrate efficiently through these L cells (Fig. 6). We then used L cells expressing PECAM-1. Again, we could not detect significant transmigration of monocytic cells. In contrast, when L cells expressing ICAM-1 were used in the assay, we found that both J774.2 and WEHI-3 beta 3+ cells were able to transmigrate very efficiently, though ICAM-1 is not a known ligand for alpha vbeta 3 (2% of added J774.2 cells and 6% of added WEHI-3 beta 3+ cells transmigrated). L cells transfected with ICAM-1 also expressed fibronectin but not fibrinogen (Fig. 7), the latter can act as a bridging molecule between ICAM-1 and the alpha Mbeta 2 integrin (38). Therefore, it was conceivable that the binding of fibronectin to alpha vbeta 3 potentiated the transmigration of monocytes across ICAM-1. However, this implied the existence of a cross talk mechanism between alpha vbeta 3 integrin and beta 2 integrins on the monocyte.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Transmigration of J774.2 and beta 3 chain transfected WEHI-3 cells across layers of untransfected L cells, L cells transfected with CD31, or L cells transfected with ICAM-1. Transmigration required the expression of the beta 3 integrin chain on monocytes (J774.2, dotted bars and WEHI-3 beta 3+, solid bars) as well as the expression of ICAM-1 on L cells. Under no circumstance did transmigration of WEHI-3 beta 3- cells occur efficiently (hatched bars). Details of the assay are described in Materials and Methods. Cell migration is expressed as a percentage of the total number of cells added per well. The data represent the arithmetic mean (± SE) of cells from three wells per condition. A representative experiment out of three is shown.


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 7.   Immunofluorescent studies on L cells transfected with ICAM-1 for expression of fibronectin and fibrinogen. L cells were cultured for 24 h and tested for fibronectin or fibrinogen expression as described in Materials and Methods. L cells transfected with ICAM-1 expressed fibronectin (A) but not fibrinogen (B).

Monocyte Migration on Recombinant Molecules

To investigate a potential cross talk mechanism, we analyzed the migratory behavior of WEHI-3 beta 3+ cells on recombinant ICAM-1. Recombinant ICAM-1 was coated on plastic at a concentration of 2.4 µM, which has been determined to be the saturating protein concentration for these assays (32). Furthermore, this concentration is consistent with the expression levels of ICAM-1 on cytokine activated e.end2 monolayers as determined by ELISA (data not shown). Monocytes are able to migrate on recombinant ICAM-1 and this migration could be decreased by antibodies against the alpha L integrin chain but not with antibodies against MHC class II molecules (Fig. 8 a). In the first 10 min after the addition of anti-alpha L, the cells begin to lose their adherent morphology and start to round up. They reduce their velocity of migration and reach a stationary phase 50 min after the addition of antibody. Cell migration was recorded during the first 40 min of the experiment.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 8.   WEHI-3 beta 3+ monocyte migration on recombinant ICAM-1. Recombinant ICAM-1 was coated at 2.4 µM in a single well of a 96-well plate. (a) The locomotion of monocytic cells without the addition of antibody (ICAM-1) or in the presence of anti-alpha L (ICAM-1 + anti-alpha L) or anti-MHC class II (ICAM-1 + anti-MHC) antibodies, was assessed by time-lapse video microscopy. (b) A small concentration of PECAM-1 (ICAM-1, PECAM) or vitronectin (ICAM-1, vn), ligands for alpha vbeta 3 integrin, coated together with ICAM-1 significantly increased the speed of locomotion of monocytes compared with migration on ICAM-1 alone (ICAM-1). In contrast, coating ICAM-1 with laminin (ICAM-1, ln) did not affect monocyte locomotion. (c) Migration on a mixture of ICAM-1 and PECAM-1 could be decreased by anti-IAP (ICAM-1, PECAM + anti-IAP). However, migration on ICAM-1 alone was not affected by anti-IAP antibodies (ICAM-1 + anti-IAP). The experiments were performed as described in Materials and Methods. The data represent the mean speed of locomotion (± SE), determined independently of ten different migrating cells for each condition. A representative experiment of three is shown in each case.

When a low concentration of PECAM-1 or vitronectin, also a ligand for alpha vbeta 3, was coated together with ICAM-1, the speed of cell locomotion increased (Fig. 8 b). In contrast, coating the same concentration of laminin together with ICAM-1 had no effect (Fig. 8 b). Subsequently, cell locomotion on a mixture of ICAM-1 and PECAM-1 could be inhibited by antibodies against IAP, the protein associated with some functions of the alpha vbeta 3 integrin. In contrast, anti-IAP did not decrease the speed of monocyte locomotion on ICAM-1 alone (Fig. 8 c). In these experiments, whereas ICAM-1 coating was at 99% saturation, coating of PECAM-1, vitronectin, or laminin was at 1% saturation. The 1% saturation of different proteins alone does not support cell adhesion or migration on surfaces (data not shown).

In addition, we observed a 1.4-fold increase in cell migration on ICAM-1 alone when alpha v was cross-linked on the cell surface by antibodies (Fig. 9 a). Cross-linking antibodies against MHC class II had no effect. To determine whether the effect of alpha v cross-linking on monocytes was specific for beta 2 integrins, or if it could also influence the activity of other integrins important in TEM such as alpha 4beta 1, we looked at monocyte migration on recombinant VCAM-1. As can be seen in Fig. 9 b, cross-linking alpha v on monocytes migrating on VCAM-1 failed to increase their speed of locomotion and cross-linking the alpha 6 integrin chain as a control also had no effect. Surface molecule cross-linking was done in the presence of a low concentration of primary antibody (10 µg/ml) plus a secondary anti-Fc antibody (10 µg/ml), to ensure capping of the integrin/MHC on the cells for lateral migration. This is contrary to the effect of antibodies used in the TEM-blocking studies. There, 50 µg/ml of primary antibody alone was used, to ensure blocking and not capping of cell surface molecules.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 9.   Migration of WEHI-3 beta 3+ monocytic cells on recombinant ICAM-1 is affected by cross-linking the alpha v integrin chain. (a) Cross-linking antibodies against alpha v (ICAM-1 + anti-alpha v) increased the speed of cell locomotion on ICAM-1 from values in the absence of alpha v cross-linking (ICAM-1), whereas cross-linking MHC class II (ICAM-1 + anti-MHC) on the cells had no effect. (b) Monocyte migration on saturating concentrations of VCAM-1 was not enhanced by cross-linking alpha v (VCAM-1 + anti-alpha v) or alpha 6 (VCAM-1 + anti-alpha 6) integrins. (c) Comparison of locomotion of beta 3+ clone 1D10 (solid bars) and beta 3- clone 3E9 (dotted bars) monocytic cells on recombinant ICAM-1 before (ICAM-1) and after (ICAM-1 + anti-alpha v) cross-linking of the alpha v integrin chain. Locomotion of clone 3E9 cells was not affected by alpha v integrin cross-linking. The experimental procedure is described in Materials and Methods. The data represent the mean speed of locomotion (± SE) determined independently, of ten different migrating cells for each condition. A representative experiment of three is shown.

Finally, we compared locomotion of cells of the WEHI-3 beta 3+ clone 1D10 with cells of the WEHI-3 beta 3- clone 3E9, on recombinant ICAM-1. Clone 1D10 and clone 3E9 cells migrated at comparable levels on ICAM-1 alone. However, after alpha v cross-linking, locomotion was enhanced only with cells of clone 1D10 (Fig. 9 c). Clone 3E9 cells did not respond to cross-linking of the alpha v integrin chain.

These experiments were repeated with the human monocytic cell line THP-1, which expresses alpha Lbeta 2 and alpha vbeta 3 integrins (tested by FACS®, data not shown). From Fig. 10 a, it is clear that locomotion of THP-1 monocytic cells on recombinant ICAM-1 was increased 2.5-fold upon cross-linking of the alpha v integrin chain, but cross-linking the alpha 6 or beta 2 integrin chains had no effect. (The anti-mouse alpha 6 antibody recognizes alpha 6 integrins on THP-1 cells as detected by FACS®; data not shown). In a further experiment, the effect of blocking alpha Lbeta 2 on monocytic cells after enhancing their migration on ICAM-1 by cross-linking alpha v, was assessed by adding an anti-alpha L antibody. As can be seen in Fig. 10 b, cell motility on ICAM-1 returned to control levels after addition of anti-alpha L, an indication that modulation of cell migration on ICAM-1 by alpha v is dependent on the function of the alpha Lbeta 2 integrin. THP-1 cell migration was also enhanced twofold on a mixture of ICAM-1/vitronectin which could be decreased by antibodies against IAP. Again, anti-IAP had no effect on monocyte migration on ICAM-1 alone (Fig. 10 c). Finally, as a control for integrin cross talk on monocytic cells, we looked at the effect of cross-linking alpha v on THP-1 cells migrating on laminin to determine whether alpha v integrins could influence alpha 6 integrins. As can be seen from Fig. 10 d, background migration on laminin was low. However, there was no increase in cell locomotion of monocytes on laminin after cross-linking the alpha v integrin chain.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 10.   Human THP-1 cell migration on ICAM-1 can be regulated by cross-linking alpha v. Recombinant ICAM-1 was coated at a saturating concentration of 2.4 µM as before. (a) Cross-linking antibodies against alpha v (ICAM-1 + anti-alpha v) increased cell locomotion from control values for ICAM-1 alone (ICAM-1), whereas cross-linking antibodies against alpha 6 (ICAM-1 + anti-alpha 6) or beta 2 (ICAM-1 + anti-beta 2) integrins had no effect. (b) The enhanced migration on ICAM-1 after cross-linking the alpha v integrin (ICAM-1 + anti-alpha v) could be decreased by antibodies against the alpha L integrin chain (ICAM-1 + anti-alpha v, + anti-alpha L). (c) Locomotion of THP-1 on a mixture of ICAM-1/vitronectin (ICAM-1, vn) was decreased by an antibody against IAP (ICAM-1, vn + anti-IAP), whereas locomotion on ICAM-1 alone (ICAM-1) was not affected by this antibody (ICAM-1 + anti-IAP). (d) THP-1 cell migration on laminin (ln) was not enhanced by cross-linking alpha v (ln + anti-alpha v) or cross-linking alpha 6 (ln + anti-alpha 6) integrins. These experiments were performed as described in Materials and Methods. The data represent the mean speed of locomotion (± SE), determined independently of ten different migrating cells for each condition. A representative experiment of three is shown.

Effect of alpha vbeta 3 Integrin Occupancy on ICAM-1 Binding

To determine the effect of alpha vbeta 3 occupancy on the function of beta 2 integrins, we investigated the ability of THP-1 monocytic cells to bind beads coated with ICAM-1 upon adherence to immobilized BSA, anti-MHC class I, ICAM-1, vitronectin, or antibodies against the integrins alpha vbeta 5 (THP-1 cells express alpha vbeta 5; data not shown), alpha vbeta 3, alpha 6, and beta 2. The data summarized in Fig. 11 a show that monocytes adherent on anti-MHC class I, anti-alpha vbeta 5, anti-alpha 6, and anti-beta 2 antibodies or ICAM-1, bound ICAM-1-coated beads at comparable levels. However, if the cells were allowed to interact with an anti-alpha vbeta 3 antibody or vitronectin, significantly fewer ICAM-1-coated beads were bound. The epitope for the anti-alpha vbeta 3 antibody used here (LM609), is near the Arg-Gly-Asp binding site of the integrin (4). Therefore, binding of the antibody to the integrin could mimic integrin occupancy. As a control, the ability of THP-1 cells to bind fibronectin-coated beads under similar conditions was assessed. Cells immobilized on anti-alpha vbeta 3 or vitronectin bound similar numbers of fibronectin coated beads as compared with cells immobilized on other substrates (Fig. 11 b). Hardly any monocytes adhered to BSA (data not shown) and there was only negligible binding of BSA-coated beads to monocytes immobilized on the different substrates (Fig. 11 b).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 11.    Inhibition of the binding of ICAM-1-coated beads to THP-1 cells immobilized on vitronectin or anti-alpha vbeta 3 antibody. (a) Cells were immobilized on plastic coated with anti-MHC class I, ICAM-1, anti-alpha 6, anti-beta 2, vitronectin, anti-alpha vbeta 3, or anti-alpha vbeta 5 and incubated with ICAM-1-coated beads. Cells immobilized on anti-alpha vbeta 3 or vitronectin bound less ICAM-1-coated beads. (b) Cells adhered to the above substrates were incubated with fibronectin- (dotted bars) or BSA-coated beads (solid bars). THP-1 cells immobilized on different substrates displayed no differential ability to bind either fibronectin- or BSA-coated beads. The bead binding assays were performed as described in Materials and Methods. Data are expressed as a binding index, that is the number of beads bound to 100 cells. Data represent the mean of ten high power fields ± SE. A representative experiment of three is shown.

Last but not least, we tested whether anti-alpha L integrin antibodies could block the binding of ICAM-1-coated beads to THP-1 cells adherent on ICAM-1. As can be seen from Fig. 12 b, addition of 50 µg/ml of this antibody dramatically reduced binding of ICAM-1-coated beads to the cells. On the other hand, addition of a control antibody against alpha 6 integrin had no effect (Fig. 12 a). Moreover, an anti-beta 1 integrin antibody reduced binding of fibronectin coated beads to THP-1 cells immobilized on ICAM-1 (Fig. 12 d), whereas the anti-alpha 6 antibody again had no effect (Fig. 12 c).


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 12.   Photomicrographs showing the attachment of ICAM-1- or fibronectin-coated beads to THP-1 cells immobilized on ICAM-1. THP-1 cells that had adhered to ICAM-1 were treated with (a) anti-alpha 6 or (b) anti-alpha L integrin antibodies at 50 µg/ml before incubation with ICAM-1-coated beads. Less ICAM-1- coated beads bound to THP-1 cells in the presence of anti-alpha L. Cells adherent to ICAM-1 were treated with anti-alpha 6 (c) or anti-beta 1 (d) integrin antibodies at 50 µg/ml before incubation with fibronectin-coated beads. Fibronectin-coated bead binding was reduced in the presence of anti-beta 1 antibodies.

    Discussion
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Although much is known about the rolling and tight adhesion steps before TEM, little is known about the events that lead to transition from tight adhesion to migration of a leukocyte on the apical surface of the endothelium and subsequent diapedesis between the endothelial cells to the basal side of the blood vessel wall. The beta 1 and beta 2 integrins mediate tight adhesion of the leukocyte to inflammatory vascular endothelium. However, induction of TEM requires a dynamic regulation of adhesion of these integrins to their respective ligands. Our results indicate that occupancy of alpha vbeta 3 integrin on monocytes can modulate beta 2 integrin-dependent adhesion to and migration on ICAM-1. This could be a mechanism which enables monocytes to overcome tight adhesion to endothelial ICAM-1 under inflammatory conditions and engage in subsequent TEM.

J774.2 monocytic cells expressing the alpha vbeta 3 integrin transmigrated through TNF-alpha -activated endothelium, whereas WEHI-3 cells deficient in this integrin were hampered in the process. TEM of J774.2 cells could be partially blocked under inflammatory conditions by antibodies against IAP, alpha 4beta 1, alpha Lbeta 2 and alpha v integrins. TEM assays carried out with primary human monocytes reinstated that beta 2 and alpha v integrins are important in this process. Transfection of beta 3 integrin chain cDNA into WEHI-3 cells resulted in expression of the alpha vbeta 3 integrin on the cell surface. These cells were then able to engage in enhanced TEM through TNF-alpha -activated endothelium which could be inhibited by antibodies against alpha L or alpha v. Although these experiments demonstrate the importance of the alpha vbeta 3 integrin in monocyte TEM, they do not reveal how the integrin is involved in the process. The integrin alpha vbeta 3 can mediate cell spreading and migration on immobilized vitronectin (41, 42), and is a molecule involved in tumor metastasis (63). The integrin is also upregulated on proliferating endothelial cells (24), and initiates a Ca+2-dependent signaling pathway that leads to endothelial cell migration and the process of angiogenesis (6, 42). To study how the alpha vbeta 3 integrin is involved in TEM, we modified the transmigration assay by using L cells instead of e.end2 cells. Neither e.end2 cells nor L cells form tight junctions, but grow to confluence on laminin-coated filters in 48 h. L cells express fibronectin, an alpha vbeta 3 integrin ligand. However, transmigration of alpha vbeta 3 integrin-positive monocytic cells was low through untransfected L cells or L cells expressing PECAM-1. This demonstrated that simply the presence of alpha vbeta 3 ligands could not ensure efficient transmigration. Surprisingly, however, beta 3+ monocytic cells were able to transmigrate effectively through ICAM-1-expressing L cells which also expressed fibronectin. ICAM-1 is not a known ligand for alpha vbeta 3 but can bind fibrinogen which in turn can interact with alpha Mbeta 2 on leukocytes (15, 39). This alpha Mbeta 2-fibrinogen-ICAM-1 association is able to mediate leukocyte TEM (38). However, since our L cells did not express fibrinogen, we ruled out this mechanism. We speculated instead that perhaps the binding of alpha vbeta 3 to fibronectin was enhancing beta 2 integrin-mediated migration of the monocytes on ICAM-1.

We used time-lapse video microscopy studies to test this hypothesis. Both murine and human monocytic cells engage in alpha Lbeta 2-dependent migration on recombinant ICAM-1. Cocoating a ligand for alpha vbeta 3 or cross-linking the alpha v integrin to mimic alpha vbeta 3 integrin occupancy increased the speed of monocyte locomotion on ICAM-1. The alpha v chain can associate with other beta  chains such as beta 1, beta 5, and beta 8 (16, 31, 68). However, cross-linking the alpha v integrin chain on beta 3 integrin-deficient WEHI-3 monocytic cells failed to enhance their locomotion on ICAM-1, indicating that beta 3 is the essential partner chain for alpha v in alpha v-mediated monocyte motility on ICAM-1. The alpha vbeta 3 integrin is functionally associated with IAP (7), since IAP has been shown to be necessary for some beta 3 integrin-dependent functions (43). The effect of anti-IAP antibodies on the migration of monocytes on the mix of ICAM-1 and PECAM-1 or ICAM-1 and vitronectin suggests that IAP is also involved in alpha vbeta 3 integrin- mediated locomotion on ICAM-1. However, as anti-IAP antibodies were able to block the TEM of monocytes to a greater degree than anti-alpha v antibodies alone, it is likely that IAP may also have an alpha vbeta 3-independent function in leukocyte TEM.

We previously showed that cross-linking the alpha v integrin chain on T lymphocytes regulates alpha 4beta 1 function and cell migration on VCAM-1 (32). However, in the present study cross-linking alpha v on monocytes migrating on VCAM-1 did not affect their speed of locomotion, indicating that the activity of alpha 4beta 1 on monocytes is not influenced by occupancy of the alpha vbeta 3 integrin. We also examined whether alpha v integrins could influence alpha 6 integrins to rule out a nonspecific cross talk mechanism between alpha v integrins and other integrins on the cell. Cross-linking alpha v on THP-1 cells migrating on laminin had no effect on their speed of locomotion. Finally, to prove that the increase in monocyte locomotion on ICAM-1 is not an artifact of integrin cross-linking, we cross-linked MHC class II on murine monocytic cells and chains from two other integrins on THP-1 cells. Cross-linking of MHC, alpha 6, or beta 2 failed to have any effect on the migration of monocytic cells on ICAM-1. Thus, cross-linking specifically the alpha v integrin chain on monocytic cells enhanced their migration on ICAM-1, and although the alpha vbeta 3 integrin modulated beta 2 integrin function, it did not modulate the function of either alpha 4beta 1 or alpha 6 integrins on these cells.

The beta 2 integrins alpha Mbeta 2 and alpha Lbeta 2 are both expressed on the monocytic cells used in our assays. Does alpha vbeta 3 modulate one or both of these integrins? The focus of our present study was the alpha Lbeta 2 integrin. ICAM-1 has five tandemly repeated Ig-like domains (21, 27), and whereas the binding site for alpha Lbeta 2 is on the first two Ig-like domains (67), the binding site for alpha Mbeta 2 is on the third Ig-like domain (18). The recombinant murine ICAM-1 used in our experiments consists of just the first two Ig-like domains which lack the alpha Mbeta 2 binding site but supports murine monocyte migration, which could be decreased by anti-alpha L antibodies. Furthermore, anti-alpha L antibodies also decreased the enhanced migration of human THP-1 cells on ICAM-1 brought about by cross-linking the alpha v integrin chain. Therefore, we concluded that alpha Lbeta 2 is a candidate beta 2 integrin that responds to occupancy of alpha vbeta 3. This does not rule out that alpha vbeta 3 integrin occupancy may also affect the activity of alpha Mbeta 2 in vivo.

The integrin alpha Lbeta 2 forms tight interactions with endothelial ICAM-1. Cell adhesion is regulated both by the affinity of the extracellular regions of integrins for their ligands and by intracellular integrin-cytoskeletal associations (29). The strength of adhesion between cell surface receptors and the substrate is therefore a key factor in the migration process (30). Previous studies have indicated an inverse correlation between adhesion and cell migration (19). Studies on the alpha IIbbeta 3 integrin revealed that high- affinity states of the receptor results in a decrease in the migration rate of the cell (29), or locking beta 1 integrins in a state of high avidity by using activating beta 1 mAb inhibits leukocyte extravasation (35). Thus, tight adhesion of receptors to their substrates is detrimental for cell locomotion. Therefore, it seemed likely that if alpha vbeta 3 occupancy could modulate monocyte locomotion on ICAM-1, this occupancy must lead to a deadhesion between alpha Lbeta 2 and ICAM-1. Monocytes adherent on anti-alpha vbeta 3 or vitronectin were less efficient in binding ICAM-1-coated beads than monocytes adherent on ICAM-1, anti-alpha vbeta 5 or other control substrates. Furthermore, monocytes adherent to anti-alpha vbeta 3 or vitronectin do not display differential ability to bind fibronectin-coated beads. This demonstrated that occupancy of alpha vbeta 3 integrin on the monocyte can decrease the cell's binding capacity to ICAM-1. ICAM-1-coated bead binding to THP-1 cells could be blocked with antibodies against alpha L. But occupancy of alpha vbeta 3 did not reduce ICAM-1-coated bead binding to the same extent as the anti-alpha L antibodies. However, if alpha vbeta 3 occupancy reduced the interactions between alpha Lbeta 2 and ICAM-1 totally, the cell would not be able to migrate on the surface of the endothelium, but would detach instead from the vessel wall. Modulation of integrin function is therefore a key concept for cell locomotion. A cell can continuously move forward only if there is a dynamic regulation of integrin mediated adhesion and deadhesion. Chemokines can differentially regulate the avidity of alpha 4beta 1 integrins by rapidly activating and deactivating them on monocytes and eosinophils (73, 74). No doubt this mechanism contributes to monocyte motility on VCAM-1. We previously showed that the alpha vbeta 3 integrin can modulate the activity of alpha 4beta 1 on T lymphocytes and enhance their migration on VCAM-1 (32). Now we demonstrate that alpha vbeta 3 can modulate the function of alpha Lbeta 2 integrins on monocytes and favor their migration on ICAM-1.

How do integrins communicate with each other? Integrins lack intrinsic enzymatic activity to trigger signaling, but several groups have shown that integrin cytoplasmic tails can bind to structural cytoskeletal proteins which in turn interact with components of the intracellular signaling machinery en route to other cell surface receptors (36, 62). Integrins can also interact directly to form cis-acting complexes on the cell surface. The beta 2 integrins serve as signaling partners for leukocyte receptors in this way. The urokinase plasminogen activator receptor (CD87) and alpha Mbeta 2 form a functional unit on monocytic cells (64). Interestingly, it has recently been shown that the urokinase plasminogen activator receptor (uPAR) is necessary for alpha Lbeta 2-mediated leukocyte migration under inflammatory conditions, and monocyte recruitment to sites of inflammation is impaired in the absence of uPAR (46). The urokinase receptor can also associate with beta 1 and beta 3 integrins on tumor cells adherent on vitronectin which may regulate tumor cell migration (75). Further work will address the mechanism by which the alpha vbeta 3 integrin regulates alpha Lbeta 2 function on the same cell in monocyte transmigration.

Peripheral blood monocytes express alpha vbeta 3 albeit at lower levels than beta 2 integrins. This level is probably sufficient to mediate the signal required to initiate cell motility on ICAM-1. However, cell motility on the ECM requires high expression levels of the integrin (5, 76). The cytokine granulocyte macrophage colony-stimulating factor (GM-CSF) can upregulate the expression levels of alpha vbeta 3 on monocytes (13), and is produced by inflammatory endothelium (50). Interestingly, it has been shown that mice transgenic for the GM-CSF gene develop accumulations of macrophages in tissues (37). Therefore, it is likely that levels of alpha vbeta 3 on monocytes immobilized to inflammatory endothelium in vivo is upregulated by the influence of GM-CSF released by the endothelium, which in turn would promote monocyte locomotion on the endothelium and the underlying ECM.

Previous studies have emphasized the requirement for an integrin hierarchy to facilitate the coordinated migration of leukocytes across the endothelium into tissues. The alpha 4beta 1 integrin is involved in the arrest and initial adhesion of rolling leukocytes to inflammatory endothelium via VCAM-1. Subsequently, alpha Lbeta 2 mediates tight adhesion of the leukocyte to vascular ICAM-1 after cellular activation (10). The alpha Lbeta 2 integrin is then able to downregulate alpha 4beta 1 and cell adhesion to VCAM-1 (52). In the next step of the integrin hierarchy, the alpha vbeta 3 integrin downregulates alpha Lbeta 2 activity, modulating leukocyte adhesion to ICAM-1, and enabling the cell to migrate effectively across the endothelium.

In summary, we show that the alpha vbeta 3 integrin is involved in the transition between tight adhesion of monocytes to the vascular endothelium and subsequent diapedesis. This may be an important mechanism not only for the TEM of monocytes but also for other leukocyte subsets that use beta 2 integrins during transendothelial diapedesis.

    Footnotes

Received for publication 11 September 1997 and in revised form 18 June 1998.

   Address all correspondence to Beat A. Imhof, Professor of Pathology, Geneva University, Department of Pathology, 1, rue Michel-Servet, CH-1211 Geneva, Switzerland. Tel.: (41) 22-702-57-47. Fax: (41) 22-702-57-46. E-mail: beat.imhof{at}medecine.unige.ch

We would like to thank P. Hammel, G. Wiedle, J.-P. Dangy, B. Ecabert, M. Dessing, S. Meyer, and S. Cooper (all from Basel Institute for Immunology, Basel, Switzerland, except Wiedle from Céntre Medicale Universitaire, Geneva, Switzerland) for their technical assistance. We would also like to thank K. Campbell and R. Torres (both from Basel Institute for Immunology) for reviewing and improving the manuscript, and H. Stahlberger, H. Spalinger, and B. Pfeiffer (all three from Basel Institute for Immunology) for artwork and photography. Finally, we thank U. Vischer for the HUVEC cultures, B. Sinha (both from Basel Institute for Immunology) for his help with experimental protocols, K. Willimann (Theador Kocher Institute, Bern, Switzerland) for reagents, and B. Englehardt (Max Planck Institute, Bad Nauheim, Germany) for advice with the transmigration assays.

This work was supported in part by grants from the Swiss National Science Foundation (3100-049241.96) and the Recherche Suisse contre le Cancer (KFS 412-1-97). The Basel Institute for Immunology was founded and is supported by F. Hoffmann-La Roche AG, CH-4005 Basel, Switzerland.

    Abbreviations used in this paper

ECM, extracellular matrix; GM-CSF, granulocyte macrophage colony-stimulating factor; HUVEC, human umbilical vein endothelial cells; IAP, integrin-associated protein; ICAM-1, intercellular adhesion molecule-1; IMDM, Iscove's modified Dulbecco's medium; MCP-1, monocyte chemoattractant protein-1; MHC, major histocompatibility complex; PECAM-1, platelet endothelial cell adhesion molecule-1; TEM, transendothelial migration; VCAM-1, vascular cell adhesion molecule-1.

    References
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Bargatze, R.F., M.A. Jutila, and E.C. Butcher. 1995. Distinct roles of L-selectin and integrins alpha 4beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity 3: 99-108
2. Berlin, C., R.F. Bargatze, J.J. Campbell, U.H. von Adrian, M.C. Szabo, S.R. Hasslen, R.D. Nelson, E.L. Berg, S.L. Erlandsen, and E.C. Butcher. 1995. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80: 413-422
3. Blystone, S.D., I.L. Graham, F.P. Lindberg, and E.J. Brown. 1994. Integrin alpha vbeta 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha 5beta 1. J. Cell Biol 127: 1129-1137 [Abstract].
4. Bombeli, T., B.R. Schwartz, and J.M. Harlan. 1998. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alpha vbeta 3 integrin and GPIbalpha . J. Exp. Med. 187: 329-339 [Abstract/Free Full Text].
5. Brando, C., and E.M. Shevach. 1995. Engagement of vitronectin receptor (alpha vbeta 3) on murine T cells stimulates tyrosine phosphorylation of a 115-kDa protein. J. Immunol 154: 2005-2011 [Abstract/Free Full Text].
6. Brooks, P.C., R.A. Clark, and D.A. Cheresh. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571
7. Brown, E., L. Hooper, T. Ho, and H. Gresham. 1990. Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J. Cell Biol. 111: 2785-2794 [Abstract].
8. Buckley, C.D., R. Doyonnas, J.P. Newton, S.D. Blystone, E.J. Brown, S.M. Watt, and D.L. Simmons. 1996. Identification of alpha vbeta 3 as a heterotypic ligand for CD31/PECAM-1. J. Cell Sci 109: 437-445 [Abstract/Free Full Text].
9. Butcher, E.C., and L.J. Picker. 1996. Lymphocyte homing and homeostasis. Science 272: 60-66 [Abstract].
10. Campbell, J.J., J. Hedrick, A. Zlotnik, M.A. Siani, D.A. Thompson, and E.C. Butcher. 1998. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279: 381-384 [Abstract/Free Full Text].
11. Clyman, R.I., F. Mauray, and R.H. Kramer. 1992. Integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp. Cell Res 200: 272-284
12. Cooper, D., F.P. Lindberg, J.R. Gamble, E.J. Brown, and M.A. Vadas. 1995. Transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc. Natl. Acad. Sci. USA 92: 3978-3982 [Abstract/Free Full Text].
13. De Nichilo, M.O., and G.F. Burns. 1993. Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages. Proc. Natl. Acad. Sci. USA. 90: 2517-2521 [Abstract].
14. DeLisser, H.M., J. Chilkotowsky, H.-C. Yan, M.L. Daise, C.A. Buck, and S.M. Albelda. 1994. Deletions in the cytoplasmic domain of platelet- endothelial cell adhesion molecule-1 (PECAM-1, CD31) result in changes in ligand binding properties. J. Cell Biol. 124: 195-203 [Abstract].
15. Diamond, M.S., and T.A. Springer. 1993. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120: 545-556 [Abstract].
16. Diamond, M.S., and T.A. Springer. 1994. The dynamic regulation of integrin adhesiveness. Curr. Biol. 4: 506-516
17. Diamond, M.S., D.E. Staunton, A.R. de Fougerolles, S.A. Stacker, A.J. Garcia, M.L. Hibbs, and T.A. Springer. 1990. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol 111: 3129-3139 [Abstract].
18. Diamond, M.S., D.E. Staunton, S.D. Marlin, and T.A. Springer. 1991. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 65: 961-971
19. Dunlevy, J.R., and J.R. Couchman. 1993. Controlled induction of focal adhesion disassembly and migration in primary fibroblasts. J. Cell Sci. 105: 489-500 [Abstract/Free Full Text].
20. Dunon, D., L. Piali, and B.A. Imhof. 1996. To stick or not to stick: the new leukocyte homing paradigm. Curr. Opin. Cell Biol. 8: 714-723
21. Dustin, M.L., R. Rothlein, A.K. Bhan, C.A. Dinarello, and T.A. Springer. 1986. Induction by IL-1 and interferon-gamma : tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J. Immunol. 137: 245-254 [Abstract/Free Full Text].
22. Felding-Habermann, B., and D.A. Cheresh. 1993. Vitronectin and its receptors. Curr. Opin. Cell Biol 5: 864-868
23. Felding-Habermann, B., S. Silletti, F. Mei, C.-H. Siu, P.M. Yip, P.C. Brooks, D.A. Cheresh, T.E. O'Toole, M.H. Ginsberg, and A.M.P. Montgomery. 1997. A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins. J. Cell Biol. 139: 1567-1581 [Abstract/Free Full Text].
24. Freidlander, M., P.C. Brooks, R.W. Shaffer, C.M. Kincaid, J.A. Varner, and D.A. Cheresh. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500-1502 [Abstract].
25. Gao, A.G., F.P. Lindberg, M.B. Finn, S.D. Blystone, E.J. Brown, and W.A. Frazier. 1996. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J. Biol. Chem 271: 21-24 [Abstract/Free Full Text].
26. Gresham, H.D., J.L. Goodwin, P.M. Allen, D.C. Anderson, and E.J. Brown. 1989. A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J. Cell Biol. 108: 1935-1943 [Abstract].
27. Horley, K.J., C. Carpenito, B. Baker, and F. Tekei. 1989. Molecular cloning of murine intercellular adhesion molecule (ICAM-1). EMBO (Eur. Mol. Biol. Organ.) J. 8: 2889-2896 [Abstract].
28. Huang, S., R.I. Endo, and G.R. Nemerow. 1995. Upregulation of integrins alpha vbeta 3 and alpha vbeta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J. Virol. 69: 2257-2263 [Abstract].
29. Huttenlocher, A., M.H. Ginsberg, and A.F. Horwitz. 1996. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J. Cell Biol. 134: 1551-1562 [Abstract].
30. Huttenlocher, A., R.R. Sandborg, and A.F. Horwitz. 1995. Adhesion in cell migration. Curr. Opin. Cell Biol 7: 697-706
31. Hynes, R.O.. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25
32. Imhof, B.A., D. Weerasinghe, E.J. Brown, F. Lindberg, P. Hammel, L. Piali, M. Dessing, and R. Gisler. 1997. Crosstalk between alpha vbeta 3 and alpha 4beta 1 integrin regulates lymphocyte migration on vascular cell adhesion molecule 1.  Eur. J. Immunol. 27: 3242-3252
33. Ishibashi, Y., S. Claus, and D.A. Relman. 1994. Bordetella pertussis filamentous hemagglutinin interacts with a leukocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/ CD18). J. Exp. Med 180: 1225-1233 [Abstract].
34. Issekutz, A.C., and T.B. Issekutz. 1995. Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late antigen 4 integrin mechanisms. J. Exp. Med 181: 1197-1203 [Abstract].
35. Kuijpers, T.W., E.P.J. Mul, M. Blom, N.L. Kovach, C.A. Gaeta, V. Tollefson, M.J. Elices, and J.M. Harlan. 1993. Freezing adhesion molecules in a state of high-avidity binding blocks eosinophil migration. J. Exp. Med 178: 279-284 [Abstract].
36. Lafrenie, R.M., and K.M. Yamada. 1996. Integrin-dependent signal transduction. J. Cell. Biochem. 61: 543-553
37. Lang, R.A., D. Metcalf, R.A. Cuthbertson, I. Lyons, E. Stanley, A. Kelso, G. Kannourakis, D.J. Williamson, G.K. Klintworth, T.J. Gonda, and A.R. Dunn. 1987. Transgenic mice expressing a hematopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 51: 675-686
38. Languino, L.R., A. Duperray, K.J. Joganic, M. Fornaro, G.B. Thornton, and D.C. Altieri. 1995. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc. Natl. Acad. Sci. USA 92: 1505-1509 [Abstract].
39. Languino, L.R., J. Plescia, A. Duperray, A.A. Brian, E.F. Plow, J.E. Geltosky, and D.C. Altieri. 1993. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1 dependent Pathway. Cell 73: 1423-1434
40. Lawrence, M.B., and T.A. Springer. 1991. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 65: 859-873
41. Leavesley, D.I., G.D. Ferguson, E.A. Wayner, and D.A. Cheresh. 1992. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J. Cell Biol. 117: 1101-1107 [Abstract].
42. Leavesley, D.I., M.A. Schwartz, M. Rosenfeld, and D.A. Cheresh. 1993. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell Biol 121: 163-170 [Abstract].
43. Lindberg, F.P., D.C. Bullard, T.E. Caver, H.D. Gresham, A.L. Beaudet, and E.J. Brown. 1996. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 274: 795-798 [Abstract/Free Full Text].
44. Lindberg, F.P., H.D. Gresham, M.I. Reinhold, and E.J. Brown. 1996. Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. J. Cell Biol. 134: 1313-1322 [Abstract].
45. Luscinskas, F.W., G.S. Kansas, H. Ding, P. Pizcueta, B.E. Schleiffenbaum, T.F. Tedder, and M.A. Gimbrone. 1994. Monocyte rolling, arrest, and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta 1 integrins, and beta 2 integrins. J. Cell Biol. 125: 1417-1427 [Abstract].
46. May, A.E., S.M. Kanse, L.R. Lund, R.H. Gisler, B.A. Imhof, and K.T. Preissner. 1998. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. In press.
47. Meerschaert, J., and M.B. Furie. 1995. The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1 and other ligands on endothelium. J. Immunol 154: 4099-4112 [Abstract/Free Full Text].
48. Miyake, K., I.L. Weissman, J.S. Greenberger, and P.W. Kincade. 1991. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J. Exp. Med 173: 599-607 [Abstract].
49. Muller, W.A., S.A. Weigl, X. Deng, and D.M. Phillips. 1993. PECAM-1 is required for transendothelial migration of leukocytes. J. Exp. Med 178: 449-460 [Abstract].
50. Nicola, N.A.. 1989. Hemopoietic cell growth factors and their receptors. Annu. Rev. Biochem 58: 45-77
51. Piali, L., P. Hammel, C. Uherek, F. Bachmann, R.H. Gisler, D. Dunon, and B.A. Imhof. 1995. CD31/PECAM-1 is a ligand for alpha vbeta 3 integrin involved in adhesion of leukocytes endothelium. J. Cell Biol 130: 451-460 [Abstract].
52. Porter, J.C., and N. Hogg. 1997. Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human T cells alters alpha 4beta 1- and alpha 5beta 1-mediated function. J. Cell Biol. 138: 1437-1447 [Abstract/Free Full Text].
53. Price, A.A., M. Cumberbatch, I. Kimber, and A. Ager. 1997. Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J. Exp. Med. 186: 1725-1735 [Abstract/Free Full Text].
54. Randolph, G.W., and M.B. Furie. 1995. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J. Immunol 155: 3610-3618 [Abstract].
55. Rosales, C., H.D. Gresham, and E.J. Brown. 1992. Expression of the 50k Da integrin-associated protein on myeloid cells and erythrocytes. J. Immunol 149: 2759-2764 [Abstract/Free Full Text].
56. Roth, S.J., M. Woldemar, Carr, and T.A. Springer. 1995. C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon gamma  inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur. J. Immunol 25: 3482-3488
57. Ruiz, P., M.V. Wiles, and B.A. Imhof. 1995. alpha 6 integrins participate in pro-T cell homing to the thymus. Eur. J. Immunol 25: 2034-2041
58. Ruoslahti, E.. 1988. Fibronectin and its receptors. Annu. Rev. Biochem 57: 375-413
59. Salcedo, R., and M. Patarroyo. 1995. Constitutive alpha V beta 3 integrin-mediated adhesion of human lymphoid B cells to vitronectin substrate. Cell. Immunol. 160: 165-172
60. Sanchez-Madrid, F., J.A. Nagy, E. Robbins, P. Simon, and T.A. Springer. 1983. A human leukocyte differentiation antigen family with distinct alpha -subunits and a common beta -subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J. Exp. Med. 158: 1785-1803 [Abstract].
61. Sanchez-Madrid, F., P. Simon, S. Thompson, and T.A. Springer. 1983. Mapping of antigenic and functional epitopes on the alpha - and beta - subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J. Exp. Med 158: 586-602 [Abstract].
62. Schaller, M.D., C.A. Otey, J.D. Hildebrand, and J.T. Parsons. 1995. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J. Cell Biol. 130: 1181-1187 [Abstract].
63. Seftor, R.E., E.A. Seftor, K.R. Gehlsen, W.G. Stetler-Stevenson, P.D. Brown, E. Ruoslahti, and M.J. Hendrix. 1992. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA 89: 1557-1561 [Abstract].
64. Simon, D.I., N.K. Rao, H. Xu, Y. Wei, O. Majdic, E. Ronne, L. Kobzic, and H.A. Chapman. 1996. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88: 3185-3194 [Abstract/Free Full Text].
65. Springer, T.A.. 1990. Adhesion receptors of the immune system. Nature 346: 425-434
66. Springer, T.A.. 1994. Traffic signals for lymphocyte recirculaton and leukocyte emigration: the multistep paradigm. Cell 76: 301-314
67. Staunton, D.E., M.L. Dustin, H.P. Erickson, and T.A. Springer. 1990. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 61: 243-254
68. Stewart, M., M. Thiel, and N. Hogg. 1995. Leukocyte integrins. Curr. Opin. Cell Biol 7: 690-696
69. Uguccioni, M., M. D'Apuzzo, M. Loetscher, B. Dewald, and M. Baggiolini. 1995. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1a and MIP-1b on human monocytes. Eur. J. Immunol. 25: 64-68
70. van Kooyk, Y., E. van de Wiel-van Kemenade, P. Weder, R.J.F. Huijbens, and C.C. Figdor. 1993. Lymphocyte function-associated antigen 1 dominates very late antigen 4 in binding of activated T cells to endothelium. J. Exp. Med. 177: 185-190 [Abstract].
71. Van Strijp, J.A.G., D.G. Russell, E. Tuomanen, E.J. Brown, and S.D. Wright. 1993. Ligand specificity of purified complement receptor type 3 (CD11b/CD18, alpha Mbeta 2): indirect effects of an Arg-Gly-Asp sequence. J. Immunol 151: 3324-3336 [Abstract/Free Full Text].
72. Vaporciyan, A.A., H.M. DeLisser, H.C. Yan, I.I. Mandiguren, S.R. Thom, M.L. Jones, P.A. Ward, and S.M. Albelda. 1993. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitement in vivo. Science 262: 1580-1582
73. Weber, C., R. Alon, B. Moser, and T.A. Springer. 1996. Sequential regulation of alpha 4beta 1 and a5beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis. J. Cell Biol. 134: 1063-1073 [Abstract].
74. Weber, C., J. Kitayama, and T.A. Springer. 1996. Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils. Proc. Natl. Acad. Sci. USA. 93: 10939-10944 [Abstract/Free Full Text].
75. Xue, W., I. Mizukami, R.F. Todd III, and H.R. Petty. 1997. Urokinase-type plasminogen activator receptors associate with beta 1 and beta 3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57: 1682-1689 [Abstract].
76. Zutter, M.M.. 1991. Immunolocalization of integrin receptors in normal lymphoid tissues. Blood 77: 2231-2236 [Abstract].

Copyright © 1998 by The Rockefeller University Press.
0021-9525/98/07/595/13 $2.00